The main goal of our research is the characterization of biomarkers that help to predict the course of the disease or the response to therapy in cancer patients.
These biomarkers should enable better use of existing therapies, help to identify new targets in cancer therapy or expand knowledge for new therapy concepts and ultimately improve the outcome of cancer patients.
To achieve this goal, we analyze tumor tissue from cancer patients for genetic or morphological changes and for the activity of various proteins.
The OncoMasTR test predicts distant recurrence in estrogen receptor-positive, HER2-negative early breast cancer: A validation study in ABCSG Trial 8
Filipits M, Rudas M, Kainz V, Singer CF, Fitzal F, Bago-Horvath Z, Greil R, Balic M, Regitnig P, Halper S, Hulla W, Egle D, Barron S, Loughman T, O’Leary D, Gallagher WM, Hlauschek D, Gnant M, Dubsky P.
Clin Cancer Res, 2021. doi: 10.1158/1078-0432.CCR-21-1023
ESR1, PGR, ERBB2 and MKi67 mRNA expression in postmenopausal women with hormone receptor-positive early breast cancer: Results from ABCSG Trial 6
Filipits M, Rudas M, Singer CF, Fitzal F, Bago-Horvath Z, Greil R, Balic M, Lax SF, Halper S, Hulla W, Wu N, Liu X, Weidler J, Bates M, Hlauschek D, Gnant M, Dubsky P.
ESMO Open 6, 100228, 2021. doi: 10.1016/j.esmoop.2021.100228
Somatic copy-number alterations in plasma circulating tumor DNA from advanced EGFR-mutated lung adenocarcinoma
Buder A, Heitzer E, Waldispühl-Geigl J, Weber S, Moser T, Hochmair MJ, Hackner K, Errhalt P, Setinek U, Filipits M.
Biomolecules 11, 618, 2021. doi: 10.3390/biom11050618
A clinical validation study of MammaPrint in Hormone Receptor positive breast cancer from the Austrian Breast and Colorectal Cancer Study Group 8 (ABCSG-8) biomarker cohort
Dubsky P, Van’t Veer L, Gnant M, Rudas M, Bago-Horvath Z, Greil R, Lujinovic E, Rinnerthaler G, Hulla W, Moinfar F, Egle D, Dreezen C, Frantal S, Filipits M.
ESMO Open 6, 100006, 2020. doi: 10.1016/j.esmoop.2020.100006
Predictive value of intrinsic luminal subtypes in premenopausal women with endocrine-responsive early breast cancer: Results from the ABCSG Trial 5
Bago-Horvath Z, Rudas M, Singer CF, Greil R, Balic M, Lax SF, Kwasny W, Hulla W, Gnant M, Filipits M.
Clin Cancer Res 26, 5682-5688, 2020. doi: 10.1158/1078-0432.CCR-20-0673
The allele frequency of EGFR mutations predicts survival in advanced EGFR T790M-positive NSCLC patients treated with osimertinib
Buder A, Hochmair MJ, Filipits M.
Targeted Oncol 16, 77-84, 2021. doi: 10.1007/s11523-020-00781-3